EU Pharma Reform is reshaping how manufacturers plan protection, access, launch sequencing, and competition. Its commercial impact will also depend on global pricing dynamics. Companies must align regulatory, access, supply, and pricing decisions earlier in the product cycle.
Pharma and biotech companies preparing EU launches face a more complex environment than the one they have been used to. Alongside the renewed US push for Most Favoured Nation (MFN) drug pricing, the EU Pharma Reform could reshape protection, access, launch sequencing, and competition well beyond Europe. Its stated aims are to improve access, reduce inequalities between Member States, strengthen availability, and preserve incentives for meaningful innovation.
Whether the EU Pharma Reform will achieve these objectives remains uncertain. It will take effect in a global pricing environment that has changed materially since the legislation was designed. Broader European launch incentives may become less attractive if lower-priced EU launches put downward pressure on US prices and revenues.
Several provisions have direct implications for access, pricing, and commercial strategy: the revised market protection structure, the product-level logic for orphan medicinal products, Article 59 and its widely discussed “launch obligation”, and the expanded Bolar exemption. These are not simply technical regulatory changes. Together, they affect protection, launch timing, market readiness, and pricing exposure in Europe.
The reform introduces new considerations that manufacturers need to address earlier in the product lifecycle and across more markets. Clinical, regulatory, access, commercial, and supply teams should coordinate sooner on evidence generation, launch timing, market readiness, supply requirements, lifecycle planning, and loss-of-exclusivity assumptions. Where local decisions affect price corridors, international reference pricing (IRP), or MFN exposure, they should also be escalated into global pricing governance.
Data protection and orphan exclusivity
For medicinal products whose marketing authorization applications are submitted after the new rules become applicable, protection will be assessed against the revised criteria set out in the EU Pharma Reform.
The current framework provides eight years of regulatory data protection plus two years of market protection. The reform would replace this with a more conditional model: eight years of regulatory data protection and one year of baseline market protection. Additional protection would depend on specific requirements, such as addressing unmet medical need, meeting defined evidence-generation and EU filing timing requirements, or securing a new indication with significant clinical benefit.
While the criteria are set out in the legislation, their practical application will depend on future guidance and regulatory practice. Companies therefore cannot assume the same protection period in every asset forecast. They should assess earlier which products may qualify for additional protection, what evidence will be required, and whether development, filing, launch, and lifecycle choices support that opportunity.
This makes early cross-functional coordination more important. Eligibility for additional market protection can depend on choices made well before launch, including clinical development design, evidence generation, and filing strategy.
Orphan medicinal products face a similar shift. Under the reformed approach, standard orphan exclusivity would be nine years, extendable to 11 years for breakthrough orphan medicinal products. Subsequent orphan marketing authorisations for the same active substance would no longer generate separate market-exclusivity periods.
Instead, they could generate limited one-year extensions, capped at two additional years in total, and only where the new indication is authorized at least two years before the end of the existing exclusivity period.
For companies with multi-indication rare-disease assets, this changes the value of indication sequencing. The first orphan indication becomes more important, while follow-on indications should be assessed earlier for clinical feasibility, potential additional protection, payer value, and fit with the product’s lifecycle strategy.
Article 59 and launch sequencing
The launch obligation is the clearest example of how the EU Pharma Reform links access objectives to commercial behavior. It is intended to address differences in how quickly new medicines become available across Member States.
Under the proposed mechanism, within one year of marketing authorization, a Member State may request that the marketing authorization holder take the necessary steps to make the product available and supply it to meet patient needs in that market. If the required steps are not taken within three years of the request, the relevant market protection and, where applicable, orphan exclusivity prolongations may cease to apply in that Member State.
For manufacturers, this adds a new scenario to European launch planning. Many companies already have a defined launch sequence, with some markets prioritized earlier and others following in later waves. Article 59 means they will need to anticipate how potential Member State requests will affect that plan, particularly where responding would have implications for supply, operating model, regulatory protection in that market, IRP, or re-referencing in other markets.
This raises two connected questions. First, can the manufacturer respond? Making a product available requires broader local coverage, market-level capabilities, and sufficient supply capacity across more EU markets than originally planned. For markets outside the company’s usual EU launch footprint, manufacturers should assess whether an affiliate, distributor, or partner can meet local requirements.
Second, should the manufacturer respond? Meeting a request can preserve protection in the requesting Member State and support the reform’s access objective, but it may also create a low-price reference with implications elsewhere. Not launching may avoid the immediate reference risk, but could mean losing protection in that Member State and facing earlier generic or biosimilar entry.
Where MFN policies are increasingly part of the global pricing debate, these trade-offs become more consequential. A launch request from a lower-price Member State is not only a local access question. It requires the company to weigh the value of preserving protection in that country against the potential impact on European price corridors, IRP, and global pricing governance.
Article 59’s implementation and practical impact remain uncertain. Companies should therefore assess where requests may arise, what capabilities they would need to respond, and which pricing risks they are willing to accept.
Expanded Bolar exemption and post-protection competition
The expanded Bolar exemption could make the effects of losing protection more immediate. It allows generic and biosimilar manufacturers to carry out certain activities before patent or supplementary protection certificate expiry without infringing the relevant rights. The policy aim is to reduce delays between the end of protection and the availability of lower-cost alternatives.
The EU Pharma Reform broadens permitted activities beyond regulatory approval to include health technology assessment, pricing and reimbursement, procurement, and tendering. This could allow generic and biosimilar manufacturers to be ready when protection expires. For health systems, it supports earlier competition, savings, and access to lower-cost alternatives.
For originators, the same change narrows the practical buffer after loss of exclusivity, particularly where market protection ceases to apply in a Member State non-compliance with a launch obligation request. In those cases, generic or biosimilar manufacturers will be better positioned to enter earlier. Originators should therefore revisit loss-of-exclusivity assumptions market by market and address them earlier in lifecycle planning.
Priorities for manufacturers
Manufacturers should focus on three priorities:
- Map the legislative implications across the portfolio, identifying which assets and future launches face the greatest risks or opportunities under the new protection, access, and competition dynamics.
- Review and, where needed, adapt internal processes and governance, including country supply-chain readiness, launch governance, pricing escalation, and lifecycle planning.
- Stay engaged in policy and implementation discussions to clarify remaining uncertainties and identify opportunities to shape follow-on guidance and national transposition.
Reform in the wider pricing landscape
A central question is whether the EU Pharma Reform will remain fit for purpose by the time it applies. The global pricing environment has also changed since the legislation was designed, including renewed US debate on MFN pricing and its potential implications for European launches.
Whether the reform makes Europe more attractive as a launch market will depend on the product, the markets involved, the value of the available incentives, and the manufacturer’s exposure to IRP and MFN-related risks. The framework may create opportunities for some assets while adding complexity to an already challenging European launch environment. Overall, however, industry perception and early company reactions appear to lean toward the view that the reform will reduce, rather than strengthen, Europe’s attractiveness. At the same time, the risk that global pricing dynamics could also lead manufacturers to delay or reconsider European launches has become increasingly relevant.
The picture can change as the broader European policy agenda develops. Further implementation and policy discussions are likely as policymakers balance access, competitiveness, supply resilience, and global pricing pressure.
Waiting until implementation would leave little room to adapt. Manufacturers that assess the implications early and align launch, pricing, supply, and lifecycle governance will be better placed to manage the trade-offs.
Thank you to Marcella Sammartino for her contribution!
Hear more insights on EU health policy from our experts:
